First-Line Immune Checkpoint Inhibitor Therapy for MSI-High Metastatic Colon Cancer

In a randomized trial, 24-month progression-free survival was significantly higher with nivolumab plus ipilimumab than with chemotherapy.

Pembrolizumab achieves superior response, progression-free survival (PFS) and overall survival compared with first-line chemotherapy in patients with microsatellite-instability (MSI)–high metastatic colorectal cancer (CRC). Nonrandomized trials have also indicated a high degree of effectiveness for single-agent nivolumab or the combination of ipilimumab and nivolumab (ipi/nivo).

Investigators now report results of the industry-sponsored, phase 3 Checkmate 8HW trial comparing treatment with first-line chemotherapy versus ipi/nivo in patients with previously untreated unresectable or metastatic MSI-high CRC. Patients were randomly assigned to treatment with investigators' choice of chemotherapy with or without a targeted agent, or nivolumab (2…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

First-Line Immune Checkpoint Inhibitor Therapy for MSI-High Metastatic Colon Cancer

Topics

Reviewing Author